1285 related articles for article (PubMed ID: 26209472)
1. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
2. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
3. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
Krüger R; Müller T; Riess O
J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
[TBL] [Abstract][Full Text] [Related]
4. Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases.
Giacomelli C; Daniele S; Martini C
Biochem Pharmacol; 2017 May; 131():1-15. PubMed ID: 28159621
[TBL] [Abstract][Full Text] [Related]
5. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.
Duka V; Lee JH; Credle J; Wills J; Oaks A; Smolinsky C; Shah K; Mash DC; Masliah E; Sidhu A
PLoS One; 2013; 8(9):e75025. PubMed ID: 24073234
[TBL] [Abstract][Full Text] [Related]
6. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
7. Multiplicity of α-Synuclein Aggregated Species and Their Possible Roles in Disease.
Gracia P; Camino JD; Volpicelli-Daley L; Cremades N
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126694
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
9. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
10. Glycation in Parkinson's disease and Alzheimer's disease.
Vicente Miranda H; El-Agnaf OM; Outeiro TF
Mov Disord; 2016 Jun; 31(6):782-90. PubMed ID: 26946341
[TBL] [Abstract][Full Text] [Related]
11. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
12. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
13. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF
Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936
[TBL] [Abstract][Full Text] [Related]
14. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
[TBL] [Abstract][Full Text] [Related]
16. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein.
Goedert M
Science; 2015 Aug; 349(6248):1255555. PubMed ID: 26250687
[TBL] [Abstract][Full Text] [Related]
17. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
Hauw JJ; Hausser-Hauw C; Duyckaerts C
Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
[TBL] [Abstract][Full Text] [Related]
18. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
Dev KK; Hofele K; Barbieri S; Buchman VL; van der Putten H
Neuropharmacology; 2003 Jul; 45(1):14-44. PubMed ID: 12814657
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview.
Matej R; Tesar A; Rusina R
Clin Biochem; 2019 Nov; 73():26-31. PubMed ID: 31400306
[TBL] [Abstract][Full Text] [Related]
20. What is strain in neurodegenerative diseases?
Tian Y; Meng L; Zhang Z
Cell Mol Life Sci; 2020 Feb; 77(4):665-676. PubMed ID: 31531680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
